Association of EGFRc.2073A>T polymorphism with decreased risk of diffusely infiltrating astrocytoma in a Brazilian case-control study

International Journal of Biological Markers

Volumn 23, Issue 3, 2008, Pages 140-146

  Barbosa, K C ^a   Oba Shinjo, S M ^a   Uno, M ^a   Carvalho, P O ^a   Rosemberg, S ^a   Aguiar, P H P ^a   Carlotti, C G ^a   Malheiros, S M F ^b   Toledo, S ^b   Lotufo, P ^a   Marie, Suely K N ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Astrocytoma; EGFR polymorphisms; PCR RFLP

Indexed keywords

ADENINE; ANTINEOPLASTIC AGENT; CYTOSINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GUANINE; THYMINE;

ADULT; AGED; ARTICLE; ASTROCYTOMA; BRAIN SURGERY; BRAZIL; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; EXON; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; RISK REDUCTION; ALLELE; BRAIN TUMOR; ETHNOLOGY; GENETICS; MIDDLE AGED; RISK; TREATMENT OUTCOME;

ADULT; AGED; ALLELES; ASTROCYTOMA; BRAIN NEOPLASMS; BRAZIL; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 58149389573     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.5394     Document Type: Article

References (29)

1. http://www.datasus.gov.br. Accessed 1 October 2008.
2. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 2002; 4: 278-99.
3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. Pathology and genetics of tumours of the nervous system, 4th ed. Lyon, France: IARC/WHO Press, 2007.
4. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109.
5. Korshunov A, Sycheva R, Golanov A. The prognostic relevance of molecular alterations in glioblastomas for patients age < 50 years. Cancer 2005; 104: 825-32.
6. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996; 6: 217-23.
7. Uno M, Oba-Shinjo SM, Wakamatsu A, et al. Association of TP53 mutation, p53 overexpression, and p53 codon 72 polymorphism with susceptibility to apoptosis in adult patients with diffuse astrocytomas. Int J Biol Markers 2006; 21: 50-7.
8. Uno M, Oba-Shinjo SM, de Aguiar PH, et al. Detection of somatic TP53 splice site mutations in diffuse astrocytomas. Cancer Lett 2005; 224: 321-7.
9. Kumar A, Petri ET, Halmos B, Boggon TJ. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 2008; 26: 1742-51.
10. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006; 33: 369-85.
11. Belda-Iniesta C, de Castro Carpeño J, Casado Sáenz E, Cejas Guerrero P, Perona R, González Barón M. Molecular biology of malignant gliomas. Clin Transl Oncol 2006; 8: 635-41.
12. Belda-Iniesta C, de Castro Carpeño J, Sereno M, González-Barón M, Perona R. Epidermal growth factor receptor and glioblastoma multiforme: molecular basis for a new approach. Clin Transl Oncol 2008; 10: 73-7.
13. Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003; 63: 6962-70.
14. Liu W, Innocenti F, Wu MH, et al. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res 2005; 65: 46-53.
15. Carpentier C, Laigle-Donadey F, Marie Y, et al. Polymorphism in Sp1 recognition site of the EGF receptor gene promoter and risk of glioblastoma. Neurology 2006; 67: 872-4.
16. Nomura M, Shigematsu H, Li L, et al. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med 2007; 4: e125.
17. Spindler KL, Nielsen JN, Lindebjerg J, Brandslund I, Jakobsen A. Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region. Int J Radiat Oncol Biol Phys 2006; 66: 500-4.
18. Liu G, Gurubhagavatula S, Zhou W, et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J 2008; 8: 129-38.
19. Gregorc V, Hidalgo M, Spreafico A, et al. Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib. Clin Pharmacol Ther 2008; 83: 477-84.
20. Hsieh YY, Chang CC, Tsai FJ, Lin CC, Tsai CH. T homozygote and allele of epidermal growth factor receptor 2073 gene polymorphism are associated with higher susceptibility to endometriosis and leiomyomas. Fertil Steril 2005; 83: 796-9.
21. Shintani S, Matsuo K, Crohin CC. Intragenic mutation analysis of the human epidermal growth factor receptor (EGFR) gene in malignant human oral keratinocytes. Cancer Res 1999; 59: 4142-7.
22. Kitao K, Yoshida S, Kennedy S, et al. Epidermal growth factor receptor and human epidermal growth factor receptor 2 gene polymorphisms in endometrial cancer in a Japanese population. Reprod Sci 2007; 14: 349-56.
23. Inagaki M, Yoshida S, Kennedy S, et al. Association study between epidermal growth factor receptor and epidermal growth factor polymorphisms and endometriosis in a Japanese population. Gynecol Endocrinol 2007; 23: 1-5.
24. Voelzke WR, Petty WJ, Lesser GJ. Targeting the epidermal growth factor receptor in high-grade astrocytomas. Curr Treat Options Oncol 2008; 9: 23-31.
25. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
26. Oba-Shinjo SM, Bengtson MH, Winnischofer SM, et al. Identification of novel differentially expressed genes in human astrocytomas by cDNA representational difference
27. ΔΔCT method. Methods 2001; 25: 402-8.
28. Liu W, Wu X, Zhang W, et al. Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res 2007; 13: 6788-95.
29. Bandrés E, Barricarte R, Cantero C, et al. Epidermal growth factor receptor (EGFR) polymorphism and survival in head and neck cancer patients. Oral Oncol 2007; 43: 713-9.